CNBC's "Fast Money" Big Pharma Breakout… And A Billionaire Boycott On Netflix 10/1/25
21 snips
Oct 1, 2025 Pharma stocks are on the rise after a significant drug pricing deal, signaling optimism in the healthcare sector. The hosts analyze technical indicators that suggest a bullish trend for major companies like Pfizer and Merck. Meanwhile, Elon Musk stirs controversy by encouraging Netflix users to cancel subscriptions, raising questions about content creation and subscriber loyalty. The discussion also touches on the broader market outlook, with S&P hitting new highs, and advice for young professionals on work-life balance.
AI Snips
Chapters
Transcript
Episode notes
Drug-Deal Spark Reprices Pharma
- President Trump's drug pricing deal removed a major regulatory overhang and lifted pharma sentiment across big-cap names.
- The market now values certainty over headline risk, prompting a potential multi-month rerating for beaten-up pharma stocks.
Buy Cheap Pharma With Policy Clarity
- Consider buying depressed pharma ETFs and large-cap names now that policy uncertainty is easing.
- Cheap multiples and strong balance sheets make selective exposure a practical way to play the move.
Underweight Positioning Supports Rally
- Health care positioning is very underweight, which supports sustainability of any rally.
- Low Medicare exposure for many pharma companies makes negotiated pricing less damaging than headlines imply.